Anavex life sciences invited to present at the b. riley securities' 2022 virtual neuro & ophthalmology conference

New york, april 26, 2022 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) diseases, today announced that christopher u missling, phd, president & chief executive officer of anavex will present at the b. riley securities' 2022 virtual neuro & ophthalmology conference on wednesday, april 27, 2022, at 11:00 am et.
AVXL Ratings Summary
AVXL Quant Ranking